"instanceType","id","uuid:ID","versionIdentifier","rationale"
"StudyVersion","StudyVersion_1","5798e314-6b62-4495-aedb-13242490d611","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
